Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel STAT3 inhibitor affects DLBCL growth

Publish date:: August 28, 2020

Key clinical point: Napabucasin, a novel inhibitor of STAT3, inhibits growth and shows synergy with doxorubicin in DLBCL.

Major finding: Napabucasin exhibited potent cytotoxicity on DLBCL xenograft tumors without obvious drug toxicity in vivo.

Study details: A panel of cell lines were treated with napabucasin and assessed for growth, viability.

Disclosures: The authors declared that they had no conflicts of interest.

Citation:

Li X et al. Cancer Letters. 2020; doi.org/10.1016/j.canlet.2020.07.032.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,